Filing Analysis
This 8-K/A amendment reports the assignment of Nasim Shomali to the Audit Committee of the Board of Directors, effective August 18, 2026. This follows a previous filing regarding her appointment to the Board.
📋 Key Facts
- Nasim Shomali appointed to the Audit Committee effective August 18, 2026.
- The Audit Committee now consists of Bader Almonawer (Chair), Jim Delshad, and Nasim Shomali.
- This is an amendment (8-K/A) to a previously filed 8-K from July 2, 2026.
NeOnc Technologies Holdings, Inc. held its 2026 annual meeting of stockholders on August 14, 2026. The meeting resulted in the election of two Class I directors and the approval of several corporate governance matters, including an equity incentive plan and the appointment of independent auditors.
📋 Key Facts
- Annual Meeting held on August 14, 2026, via live webcast.
- Quorum was established with 20,208,635 shares (77.92% of outstanding shares) present in person or by proxy.
- Victoria Medvec, Ph.D. and Steven L. Giannotta, M.D. were elected to the Board of Directors for three-year terms ending in 2029.
- Stockholders approved the amendment of the 2023 Equity Incentive Plan.
- Stockholders ratified the appointment of CBIZ CPAs P.C. as independent registered public accounting firm for fiscal year 2026.
- Stockholders approved the adjournment of the Annual Meeting if necessary.
NeOnc Technologies Holdings, Inc. held an investor conference call on August 12, 2026, to discuss the Phase 2a clinical trial results for its NEO100-01 program. The filing provides a transcript of the discussion as Exhibit 99.1.
📋 Key Facts
- The company hosted an investor conference call on August 12, 2026.
- The primary topic was results from the Phase 2a portion of the NEO100-01 clinical trial.
- A transcript of the conference call is furnished as Exhibit 99.1.
NeOnc Technologies Holdings, Inc. issued a press release announcing Phase 2a clinical data results for its NEO100-01 study. The company also hosted an investor conference call to discuss the findings.
📋 Key Facts
- Announced results from the Phase 2a portion of the NEO100-01 study on August 12, 2026.
- Conducted an investor conference call to present and discuss clinical data.
- Provided a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2) regarding the data.
NeOnc Technologies Holdings, Inc. announced its Q2 financial results and scheduled an investor presentation for August 12, 2026, to discuss topline data from its Phase 2a NEO100 clinical trial.
📋 Key Facts
- Company reported second quarter financial results on August 10, 2026.
- Topline results from the fully enrolled Phase 2a NEO100 study are expected to be presented on August 12, 2026.
- An investor conference call and webcast is scheduled for Wednesday, August 12, 2026, at 8:30 a.m. ET.
NeOnc Technologies Holdings, Inc. issued a press release regarding written feedback from the FDA concerning the CMC (chemistry, manufacturing, and controls) development program for its lead drug candidate, NEO212.
🚩 Red Flags
- Regulatory feedback from the FDA can sometimes imply requests for additional data or manufacturing process changes, which may impact timelines and costs (though specific nature of feedback is not detailed in this 8-K).
📋 Key Facts
- The company received written feedback from the U.S. Food and Drug Administration (FDA).
- Feedback pertains to the chemistry, manufacturing, and controls (CMC) development program for NEO212.
- NEO212 is a novel temozolomide-perillyl alcohol conjugate.
NeOnc Technologies Holdings, Inc. announced the immediate resignation of Class II director Ming-Fu (Alan) Chiang from both the Board and the Scientific Advisory Board. Simultaneously, Nasim Shomali was elected to the Board as a Class II director.
🚩 Red Flags
- Related-party transaction/connection: The newly appointed director (Nasim Shomali) is the niece of the CEO and Executive Chairman (Amir Heshmatpour).
📋 Key Facts
- Ming-Fu (Alan) Chiang resigned as a Class II director and from the Scientific Advisory Board effective June 27, 2026.
- The Company stated Dr. Chiang's resignation was not due to any disagreement regarding operations, policies, or practices.
- Nasim Shomali elected to the Board on July 1, 2026, to serve until the 2027 annual meeting.
- Ms. Shomali previously served as a Strategy Executive at Accenture (2013-2026).
- Ms. Shomali is the niece of Amir Heshmatpour, the Company's President, CEO, and Executive Chairman.
NeOnc Technologies Holdings, Inc. announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for its lead candidate, NEO100.
📋 Key Facts
- Lead candidate: NEO100 (intranasally administered purified perillyl alcohol).
- Regulatory milestone: Granted IND status by the Department of Health – Abu Dhabi (DOH).
- Mechanism of action: Designed for non-invasive nose-to-brain delivery.
- Filing date: June 23, 2026.
NeOnc Technologies Holdings announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO212, an oral conjugate for aggressive brain tumors.
📋 Key Facts
- IND status granted by the Department of Health – Abu Dhabi (DOH) on June 16, 2026.
- The drug candidate is NEO212, an orally administered perillyl alcohol-temozolomide carbamate conjugate.
- The target indication is aggressive brain tumors.
NeOnc Technologies Holdings entered into a Securities Purchase Agreement on June 10, 2026, to sell up to $5,000,000 of Series A Convertible Preferred Stock to accredited investors. The offering includes complex conversion terms and a redemption mechanism that can lead to significant common stock dilution.
🚩 Red Flags
- Death-spiral potential: The conversion price is set at a 20% discount to the lowest closing price of the preceding 5 days, which often leads to predatory dilution in micro-cap stocks
- Multiple 8-K items: The filing triggers Items 1.01, 3.02, 3.03, 5.03, and 9.01
- Complex redemption/conversion structure: The 'conversion only if not redeemed' clause creates an incentive for the company to avoid redemption to prevent dilution, or for investors to force conversion if the stock price drops
📋 Key Facts
- Aggregate offering amount: up to $5,000,000
- Security: Series A Convertible Preferred Stock (up to 6,000 shares)
- Purchase price: $833.34 per share
- Stated value: $1,000 per share
- Conversion Price: 80% of the lowest closing price of common stock during the 5 trading days prior to conversion (floor price of $1.00)
- Redemption: Company can redeem shares within 4 months (with two 1-month extension options), adding $50 per share per extension
- Conversion Trigger: Conversion is only available if the Company elects NOT to redeem the shares by the deadline
NeOnc Technologies Holdings, Inc. issued a press release on May 18, 2026, reporting its financial results for the first quarter. The filing follows standard disclosure protocols under Items 2.02 and 7.01 for quarterly earnings updates.
📋 Key Facts
- The company reported Q1 financial results on May 18, 2026.
- The disclosure was made under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- The press release is included as Exhibit 99.1.
- The filing was signed by Amir Heshmatpour, CEO, President, and Executive Chairman.
NeOnc Technologies Holdings, Inc. entered into its fourth Securities Purchase Agreement of 2026, raising approximately $2 million through the sale of 277,777 shares and warrants to a single investor. The proceeds are earmarked for NEO216 preclinical trials, continuing a series of private placements that have raised over $15 million since January.
🚩 Red Flags
- Frequent, piecemeal financing (four separate agreements in four months) suggests a high cash burn rate or difficulty securing a single large-scale funding round.
- Potential for significant dilution from the issuance of warrants with a $9.00 exercise price.
- The offering terminates on April 30, 2026, indicating a narrow window for the remaining 406,694 shares in this tranche.
📋 Key Facts
- Sale of 277,777 shares of common stock at $7.20 per share on April 20, 2026.
- Issuance of 277,777 five-year warrants with an exercise price of $9.00 per share.
- Gross proceeds of approximately $2,000,000 from the latest closing.
- This represents the fourth separate Securities Purchase Agreement since January 29, 2026.
- Total capital raised across the series of agreements exceeds $15 million from multiple institutional and private investors.
- Proceeds are specifically designated to fund NEO216 preclinical trials.
NeOnc Technologies Holdings, Inc. announced that its Chairman and CEO, Amir Heshmatpour, purchased approximately $300,000 of the company's common stock. The company also used the announcement to provide additional context regarding operating expense increases reported in its 2025 Annual Report.
🚩 Red Flags
- The need to issue a press release to provide 'additional context' for operating expenses in a previously filed 10-K suggests potential investor concern regarding cost management or reporting clarity.
📋 Key Facts
- Chairman and CEO Amir Heshmatpour purchased approximately $300,000 worth of NTHI stock during the week of April 7-14, 2026.
- The filing provides clarification on year-over-year operating expense changes reported in the Form 10-K filed on March 31, 2026.
- The disclosure was made under Item 7.01 (Regulation FD) and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
NeOnc Technologies Holdings, Inc. has established an at-the-market (ATM) equity program to sell up to $75 million of common stock. The sales will be conducted through BTIG, LLC and A.G.P./Alliance Global Partners at a 3% commission rate.
🚩 Red Flags
- Potential for significant shareholder dilution if the full $75 million ATM facility is utilized, especially for a micro-cap company.
📋 Key Facts
- Entered into an Equity Distribution Agreement on April 10, 2026, with BTIG, LLC and A.G.P./Alliance Global Partners.
- The program allows for the sale of up to $75,000,000 in common stock from time to time.
- The company will pay a commission of 3.0% of the gross proceeds to the placement agents.
- The offering is conducted under a Form S-3 registration statement (File No. 333-294845) which became effective on April 9, 2026.
- The company has no obligation to sell any shares and can suspend or terminate the agreement at any time.
NeOnc Technologies Holdings, Inc. (NTHI) filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were initially disclosed via a press release on April 1, 2026, and formally reported under Items 2.02 and 7.01.
📋 Key Facts
- Reported financial results for Q4 and full year ended December 31, 2025
- Press release issued on April 1, 2026
- Filing signed by CEO Amir Heshmatpour on April 3, 2026
- Common stock par value is $0.0001
NeOnc Technologies entered into its third Securities Purchase Agreement (SPA) since January 2026, raising $1 million through a private placement of 138,889 shares and warrants. This transaction is part of a series of offerings intended to sell up to 2,222,222 shares at $7.20 per share for working capital purposes.
🚩 Red Flags
- Serial private placements: Three separate Securities Purchase Agreements within a three-month period (Jan, Feb, March 2026).
- High frequency of small capital raises suggests immediate liquidity needs for working capital.
- Potential dilution from 1:1 warrant coverage at a $9.00 exercise price.
📋 Key Facts
- Entered into a third SPA on March 20, 2026, to sell remaining shares from a 2,222,222 share authorization.
- Raised $1,000,000 in the initial closing of this third SPA from one investor.
- Securities issued include 138,889 shares of common stock and five-year warrants to purchase 138,889 shares.
- Purchase price set at $7.20 per share with a warrant exercise price of $9.00.
- Previous closings under two prior SPAs in Jan/Feb 2026 raised approximately $12.07 million.
- The company must file a resale registration statement within 10 days of filing its 2025 Form 10-K.
NeOnc Technologies Holdings, Inc. appointed David Choi as Chief Accounting Officer, effective March 12, 2026. Mr. Choi, a CPA with experience at Blythe Global Advisors and Big 4 firms, will oversee the company's accounting and financial reporting infrastructure.
📋 Key Facts
- David Choi appointed as Chief Accounting Officer (CAO) effective March 12, 2026.
- Base salary set at $162,500 per year.
- Granted 170,000 restricted shares, with 53,333 vesting immediately on the start date.
- Remaining equity includes 58,333 shares vesting after one year and 58,334 shares subject to performance-based metrics.
- Mr. Choi previously served as a Director at Blythe Global Advisors from 2021 to 2026.
NeOnc Technologies Holdings, Inc. announced clinical data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212. The company conducted an investor conference call on March 4, 2026, to discuss the results and provided a transcript and presentation as exhibits.
📋 Key Facts
- Announced data from Phase 1/2 clinical trial for NEO212 on March 4, 2026.
- The data pertains specifically to the dose-escalation portion of the trial.
- Hosted an investor conference call and provided a transcript (Exhibit 99.3) and presentation (Exhibit 99.2).
- The filing is made under Item 7.01 (Regulation FD Disclosure).
NeOnc Technologies Holdings settled a long-standing legal dispute with Fox Infused, LLC regarding the termination of an IP license and supply agreement. The company paid a total of $737,920.77, which included the original $600,000 settlement amount plus $137,920.77 in interest.
🚩 Red Flags
- Significant delay in settlement payment, occurring nearly two years after the March 2024 deadline
- High interest penalty of approximately 23% ($137,920.77) relative to the $600,000 principal
📋 Key Facts
- NeOnc terminated an Intellectual Property License and Supply Agreement with Fox Infused on April 25, 2023
- Fox Infused initiated litigation in June 2023, which subsequently moved to arbitration
- A settlement was reached requiring a $600,000 payment by March 31, 2024, or the closing of an IPO
- Payment was finally made on February 27, 2026, totaling $737,920.77
- The final payment included $137,920.77 in accrued interest due to the payment delay
NeOnc Technologies Holdings, Inc. entered into a new Securities Purchase Agreement on February 24, 2026, to raise capital through a private placement of common stock and warrants. This follows a previous January 2026 offering, with the current closing raising approximately $1.45 million from four investors.
🚩 Red Flags
- Frequent capital raises: The company conducted two separate offerings within a one-month span (January and February 2026), suggesting high cash burn.
- Dilutive impact: The issuance of shares and warrants at $7.20 and $9.00 respectively will dilute existing shareholders.
- Reliance on private placements (PIPEs) for working capital.
📋 Key Facts
- The company issued 201,390 shares of common stock at a price of $7.20 per share.
- The company issued 201,390 five-year warrants with an exercise price of $9.00 per share.
- The initial closing of this specific agreement on February 25, 2026, resulted in gross proceeds of $1,450,004.
- This follows a January 2026 offering that raised approximately $10.62 million.
- The company committed to filing a resale registration statement within 10 days of filing its 2025 Annual Report on Form 10-K.
- The offering terminated on February 28, 2026.
NeOnc Technologies Holdings announced an upcoming investor conference call and webcast scheduled for March 4, 2026. The company intends to present initial data from the Phase 1 dose-escalation portion of its NEO212-01 Phase 1/2 clinical trial.
📋 Key Facts
- Investor call and webcast scheduled for March 4, 2026, at 9:00 a.m. ET.
- Presentation will cover initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial.
- The disclosure was made under Item 7.01 (Regulation FD) and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement to issue and sell up to 2,222,222 shares of common stock at $7.20 per share, accompanied by five-year warrants with an exercise price of $9.00.
🚩 Red Flags
- Dilutive financing structure involving warrants with an exercise price above the current purchase price ($9.00 vs $7.20).
- Use of proceeds specifically mentions 'repayment of indebtedness', suggesting liquidity constraints.
- Issuance is via unregistered securities (Section 4(a)(2) exemption), which often indicates a need for immediate capital.
📋 Key Facts
- Total potential issuance: Up to 2,222,222 shares and corresponding warrants.
- Initial closing amount: $10 million for 1,388,888 shares and warrants.
- Share purchase price: $7.20 per share.
- Warrant terms: Five-year term with an exercise price of $9.00 per share.
- Use of proceeds: Repayment of indebtedness and working capital.
- Registration requirement: Company must file a resale registration statement within 10 days of the initial closing.
NeOnc Technologies Holdings, Inc. issued a press release regarding updated clinical results for its intranasal NEO100 treatment in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma.
📋 Key Facts
- The company reported Phase 1/2a and compassionate-use experience data.
- The study evaluates the efficacy of intranasal NEO100.
- Target patient population: recurrent WHO Grade III/IV IDH1-mutant astrocytoma.
- Filing date for report: December 17, 2025; Event date: December 15, 2025.
NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement to sell 111,732 shares of common stock to an investor for approximately $1 million. The proceeds are intended for working capital, and the company will file a resale registration statement within ten days.
🚩 Red Flags
- Unregistered sale of equity securities (Section 4(a)(2) exemption)
- Potential dilution for existing shareholders via upcoming resale registration statement
📋 Key Facts
- Date of agreement: December 1, 2025
- Investor: Saad Naja
- Shares issued: 111,732 shares of common stock
- Purchase price per share: $8.95 (based on Nov 28, 2025 closing price)
- Total proceeds: Approximately $1 million
- Use of proceeds: Working capital
- Registration requirement: Company to file a resale registration statement within 10 days of the agreement date.
NeOnc Technologies Holdings reported significant board reshuffling involving the resignation of a director due to university objections and the re-election of Dr. Ming-Fu Chiang. The filing also discloses extensive related-party transactions, including high-interest bridge loans and line of credit agreements with entities owned by directors.
🚩 Red Flags
- Significant related-party debt: The company has extensive borrowing and conversion arrangements with HCWG LLC, an entity owned by several directors.
- Governance instability: A director (Ishwar K. Puri) was forced to resign due to third-party (University of Southern California) objections shortly after appointment.
- Complex debt structures: Use of high Original Issue Discount (OID) on bridge loans and warrants issued to related parties.
📋 Key Facts
- Ishwar K. Puri resigned from the Board on November 12, 2025, following objections from the University of Southern California regarding his appointment.
- Dr. Ming-Fu Chiang was re-elected to the Board effective immediately, serving until the 2026 annual meeting.
- The Company converted $11,748,464 in Bridge Loan debt with HCWG LLC (owned by directors) into 979,039 shares of common stock at $12 per share on June 14, 2024.
- A $10.0 million Line of Credit Agreement exists with HCWG LLC bearing 10% interest, increasing to 14% if extended.
- The Company previously entered into a settlement agreement with Orient EuroPharma Co., Ltd. (partially owned by Dr. Chiang) involving a $4,000,000 payment.
NeOnc Technologies Holdings, Inc. issued a press release regarding updated clinical results from its Phase 1/2a and compassionate care studies for NEO100 in patients with recurrent IDH1-mutant astrocytoma.
📋 Key Facts
- Clinical study cohort: 24 patients with recurrent WHO Grade III/IV isocitrate dehydrogenase 1 (IDH1)-mutant astrocytoma.
- Investigational agent: NEO100 (intranasal administration).
- Filing date: November 12, 2025.
- The company hosted an investor conference call to discuss the clinical results.
NeOnc Technologies Holdings, Inc. announced an upcoming investor conference call and webcast scheduled for November 12, 2025. The event will focus on presenting data updates from the ongoing Phase 1/2a NEO100-1 clinical trial and its compassionate use program.
📋 Key Facts
- Investor conference call and webcast scheduled for Wednesday, November 12, 2025, at 9:00 a.m. ET.
- The presentation will cover data updates from the Phase 1/2a NEO100-1 clinical trial.
- Updates will also include information regarding the company's compassionate use program.
NeOnc Technologies Holdings, Inc. announced a significant leadership transition where Dr. Thomas Chen resigned as CEO to become CMO/CSO, while Amir Heshmatpour was appointed CEO. The filing also discloses extensive related-party transactions and debt conversions involving Mr. Heshmatpour.
🚩 Red Flags
- Significant related-party transactions: Mr. Heshmatpour owns 34.4% of the company and his entity (AFH) has received substantial fees ($2.5M+).
- Complex debt structures involving high Original Issue Discounts (OID) of 50% on loans from entities controlled by insiders.
- Concentration of power: The new CEO is also the Executive Chairman and a major shareholder with significant equity grants.
- History of large losses on debt extinguishment related to insider-linked bridge loans.
📋 Key Facts
- Dr. Thomas Chen resigned as CEO effective October 31, 2025; transitioning to CMO and CSO roles.
- Amir Heshmatpour appointed CEO effective October 31, 2025 (previously President and Executive Chairman).
- Mr. Heshmatpour will receive 1,200,000 shares of restricted stock as part of his new appointment.
- The Company disclosed a prior debt conversion where $11,748,464 in Bridge Loans were converted to 979,039 shares at $12/share, resulting in a $2,069,923 loss on extinguishment.
- Mr. Heshmatpour holds an aggregate of 34.4% of the fully diluted issued and outstanding common shares through AFH and affiliated entities.
NeOnc Technologies Holdings, Inc. announced that His Highness Sheikh Nahyan bin Zayed Al Nahyan will assume the role of Executive Chairman of its Middle East subsidiary, NuroMENA Holdings Ltd.
📋 Key Facts
- Announcement date: October 28, 2025
- New appointment: His Highness Sheikh Nahyan bin Zayed Al Nahyan to become Executive Chairman of NuroMENA Holdings Ltd. (Middle East subsidiary)
- The filing is a Regulation FD disclosure under Item 7.01
NeOnc Technologies Holdings, Inc. announced that its $50 million strategic partnership is nearing completion following regulatory approvals in the United Arab Emirates. The closing of this transaction is expected to occur no later than October 23, 2025.
🚩 Red Flags
- The filing is under Item 7.01 (Regulation FD Disclosure), meaning the information is 'furnished' rather than 'filed', which provides less liability protection for the company regarding the accuracy of the press release.
📋 Key Facts
- Strategic partnership value: $50 million
- Closing deadline: No later than October 23, 2025
- Regulatory status: Received all necessary tax identification and regulatory approvals from the United Arab Emirates
- Filing date of event: October 6, 2025
NeOnc Technologies Holdings, Inc. entered into a Master Services Agreement (MSA) with Insights Pharmaceutical Research LLC (IROS) to support clinical development programs in the UAE. The agreement includes an initial work order for a Phase 2b/3 study of NEO100 for Glioblastoma Multiforme.
🚩 Red Flags
- The agreement involves a subsidiary (NuroCure) that is not yet fully incorporated, adding execution complexity.
📋 Key Facts
- Entered into Master Services Agreement (MSA) with Insights Pharmaceutical Research LLC (IROS) on October 4, 2025.
- IROS is an affiliate of Group 42 Holding Ltd. and Mubadala Investment Company PJSC.
- The MSA will be transferred to the company's controlled UAE subsidiary, NuroCure, upon incorporation.
- Initial work order covers a multi-site, randomized Phase 2b/3 study for NEO100 in patients with Grade III Astrocytomas and Glioblastoma Multiforme (GBM).
- Estimated budget for the first work order is approximately $2.4 million in service fees and $0.1 million in pass-through costs.
- Payments are structured in four milestone-based installments through study completion.
NeOnc Technologies Holdings, Inc. announced that the FDA has authorized the company to proceed with Phase IIa/IIb of its NEO212-01 clinical trial. This is a regulatory development regarding their clinical pipeline.
📋 Key Facts
- FDA authorization received for Phase IIa/IIb of the NEO212-01 clinical trial.
- Announcement date: September 10, 2025.
- The filing is made under Item 7.01 (Regulation FD Disclosure) and does not constitute 'filed' information subject to Section 18 liabilities.
NeOnc Technologies Holdings, Inc. completed the acquisition of 100% of JandB Holdings, LLC via a share exchange agreement. The transaction involved issuing approximately 120,000 shares of common stock at an attributed value of $25 per share.
🚩 Red Flags
- Related-party transaction: The acquisition involves Ishwar Puri, who was a 50% owner of the target company and has been immediately appointed to the Board.
- Multiple 8-K items in a single filing (Acquisition + Officer Change).
📋 Key Facts
- Acquired 100% of the membership interests of JandB Holdings, LLC on August 18, 2025.
- Consideration: Issuance of ~120,000 shares of common stock (valued at $25/share) plus additional shares to cover transaction fees.
- JandB is now a wholly owned subsidiary of NeOnc Technologies Holdings, Inc.
- Ishwar Puri, a 50% member of JandB, has been elected to the Company's Board of Directors.
- Dr. Ming-Fu Chiang resigned from the Board effective August 18, 2025, but will remain on the science advisory board.
NeOnc Technologies Holdings, Inc. is restating its March 31, 2025 Form 10-Q due to an error in calculating non-cash share-based compensation expense for restricted stock units (RSUs) issued to management.
🚩 Red Flags
- Restatement of previously issued financial statements (Item 4.02).
- Error specifically relates to compensation expenses for management RSUs, which can sometimes signal internal control weaknesses regarding equity administration.
- The filing is an 'Amendment No. 1' to a previous 8-K, indicating ongoing reporting corrections.
📋 Key Facts
- The company discovered an error in the Form 10-Q filed on May 9, 2025, regarding the quarter ended March 31, 2025.
- The error involved the overstatement of non-cash share-based compensation expense related to 1,486,667 RSUs issued on January 4, 2024.
- The mistake was caused by incorrectly assuming all RSUs were fully vested as of March 31, 2025, whereas they actually vest over a 22-month period (only 15 months had vested at the reporting date).
- Management and the Audit Committee have concluded that the unaudited consolidated financial statements for the quarter ended March 31, 2025, should no longer be relied upon.
- The restatement is presented in the Form 10-Q for the quarter ended June 30, 2025.
NeOnc Technologies Holdings, Inc. has determined that its March 31, 2025 Form 10-Q should no longer be relied upon due to an error in calculating share-based compensation expense for restricted stock units (RSUs). The company incorrectly assumed all RSUs were fully vested by the end of Q1 2025 rather than recognizing them over a 22-month vesting period.
🚩 Red Flags
- Non-reliance on previously issued financial statements (Item 4.02).
- Error specifically relates to compensation for members of management, which can raise concerns regarding internal controls over financial reporting.
- Restatement indicates a failure in the accounting treatment of equity-based compensation.
📋 Key Facts
- Error identified on August 13, 2025, regarding the March 31, 2025 Form 10-Q filed on May 9, 2025.
- The error involves 1,486,667 restricted stock units (RSUs) issued to management on January 4, 2024.
- The company incorrectly assumed full vesting as of March 31, 2025, instead of recognizing the expense over a 22-month period.
- The restatement is fully presented in the Form 10-Q for the quarter ended June 30, 2025.
NeOnc Technologies Holdings, Inc. announced two non-material updates via press releases: the receipt of a $2.5 million NIH STTR grant and the incorporation of NuroMENA Holdings Ltd. in Abu Dhabi.
📋 Key Facts
- Awarded $2.5 million in NIH STTR Grants to advance NEO212 for Gliomas and Leukemia (announced Aug 7, 2025).
- Official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (announced Aug 11, 2025).
NeOnc Technologies Holdings, Inc. entered into a subscription agreement via its subsidiary NuroMENA for an initial $400,000 investment from Quazar For Investment in Commercial Enterprises & Management LLC, with a massive contingent follow-on investment of up to $50 million. The deal involves significant equity dilution of the parent company's interest in its subsidiary.
🚩 Red Flags
- Extreme dilution: The parent company's ownership in its subsidiary drops from 100% to 38% under the proposed terms.
- Contingent nature: Effectiveness is dependent on the incorporation of a subsidiary that 'has yet to occur'.
- High valuation/Speculative capital: A $50 million follow-on investment at a $69.6M valuation for a micro-cap's subsidiary represents significant concentration risk and potential volatility.
📋 Key Facts
- Initial subscription amount: $400,000 for 2,500,000 newly issued shares in NuroMENA.
- Quazar to lead an additional investment round of up to $50 million at $25 per share.
- The follow-on investment is based on a fully diluted pre-investment valuation of $69.6 million.
- Parent company (NeOnc) interest in NuroMENA will be diluted from 100% down to 80% initially, and potentially down to 38% after the follow-on round.
- The agreement is contingent upon the formal incorporation of NuroMENA Holdings Ltd.
NeOnc Technologies Holdings, Inc. entered into a binding Letter of Intent (LOI) to acquire all equity interest of a new LLC formed by Dr. Ishwar Puri and Beth Levinson via a share exchange transaction. The deal involves the acquisition of US Patent No 11,788,057 B2 from McMaster University through an intermediary structure.
🚩 Red Flags
- Complex multi-step transaction involving a newly formed LLC and an intermediary patent transfer.
- Use of a $500,000 promissory note that is subsequently forgiven (non-cash liability settlement).
- Potential dilution through the issuance of 120,000 shares at a fixed valuation ($25/share) which may differ from current market price.
📋 Key Facts
- Entered into a binding LOI on July 24, 2025, with Dr. Ishwar Puri and Beth Levinson.
- The transaction involves the acquisition of all equity interest in a to-be-formed Delaware LLC via share exchange.
- The LLC will acquire US Patent No 11,788,057 B2 from McMaster University for $500,000.
- Company will issue a $500,000 promissory note to the LLC to fund the patent purchase; this note is to be forgiven upon closing.
- Consideration includes 120,000 shares of common stock (valued at $25/share) less transaction fees.
- Dr. Ishwar K. Puri will be appointed to the Company’s Board of Directors upon closing.
NeOnc Technologies Holdings, Inc. announced the execution of a Sub-License Agreement with its Abu Dhabi onshore operating subsidiary, NuroCure.
🚩 Red Flags
- The transaction is with a wholly-owned/operating subsidiary, which may be an internal restructuring rather than a third-party revenue generator.
📋 Key Facts
- Agreement Date: July 22, 2025
- Counterparty: NuroCure (an Abu Dhabi onshore operating subsidiary)
- Nature of agreement: Sub-License Agreement
- Filing Type: Regulation FD Disclosure (Item 7.01)
NeOnc Technologies Holdings, Inc. entered into agreements to issue $5,000,000 in Convertible Promissory Notes to unaffiliated accredited investors. The notes feature a significant 20% original issue discount and extremely short-term maturity dates in October 2025.
🚩 Red Flags
- Extremely short maturity window (approx. 3 months from report date).
- High cost of capital via a 20% original issue discount.
- Death spiral feature: Conversion price is linked to a significant discount (80%) of the lowest closing price prior to conversion in default scenarios.
- Potential for massive dilution due to the combination of high OID and discounted conversion terms.
📋 Key Facts
- Aggregate principal amount of issued Convertible Promissory Notes is $5,000,000.
- Notes carry an original issue discount (OID) of 20%.
- Maturity dates are set for October 16, 2025, and October 18, 2025.
- Company has the option to extend maturity by up to three one-month periods; each extension adds a 5% OID penalty.
- Conversion price is set at 80% of the lowest closing sale price during the five trading days prior to conversion in the event of default.
NeOnc Technologies Holdings, Inc. announced the signing of a non-binding term sheet with Quazar Investment to establish a new investment and clinical platform in the UAE targeting the MENA region.
🚩 Red Flags
- The agreement is currently 'non-binding', meaning there is no legal obligation for either party to proceed with the partnership at this stage.
📋 Key Facts
- Signed a non-binding term sheet with Quazar Investment on July 8, 2025.
- The partnership aims to form a UAE-based investment and clinical platform.
- Focus of the new platform is the Middle East and North Africa (MENA) region.
Neonc Technologies Holdings, Inc. announced the appointment of Dr. Neman to the position of Chief Clinical Officer via a press release on June 6, 2025.
📋 Key Facts
- Dr. Neman has been appointed as Chief Clinical Officer.
- The announcement was made via a press release dated June 6, 2025.
- The filing is categorized under Item 7.01 (Regulation FD Disclosure).
NeOnc Technologies Holdings, Inc. announced the appointment of Josh Neman as Chief Clinical Officer, effective June 5, 2025. The appointment includes a base salary and an equity incentive package involving restricted stock units (RSUs).
📋 Key Facts
- Josh Neman appointed as Chief Clinical Officer effective June 5, 2025.
- Base salary set at $165,000 per year.
- Grant of 200,000 Restricted Stock Units (RSUs) under the 2023 Equity Incentive Plan.
- RSU vesting schedule: 1/3 on Dec 30, 2025; 1/3 in 29 equal monthly installments; 1/3 based on performance metrics.
- Mr. Neman previously served as Associate Professor and Scientific Director at Keck School of Medicine (USC).
NeOnc Technologies Holdings, Inc. announced the retirement of its Chief Operating Officer, Patrick Walters, effective June 1, 2025.
📋 Key Facts
- Patrick Walters is retiring from his position as Chief Operating Officer (COO).
- The departure is effective May 31/June 1, 2025.
- Notification was provided to the Board of Directors on May 28, 2025.
NeOnc Technologies Holdings, Inc. announced the appointment of Executive Chairman Amir Heshmatpour as President and disclosed extensive related-party transactions involving Mr. Heshmatpour and his entities.
🚩 Red Flags
- Extensive related-party transactions involving the Executive Chairman (Amir Heshmatpour) including advisory fees, debt conversions, and personal advances.
- High concentration of ownership/control by a single individual and his affiliates (34.4% stake).
- Significant cash outflows to the Chairman ($2.5M fee following listing; $600k repayment on personal advances with 50% OID).
- Complex debt structures involving high Original Issue Discounts (OID) and conversions to equity involving insiders.
📋 Key Facts
- Amir Heshmatpour appointed as President effective April 8, 2025; he will receive $1/month until a formal agreement is finalized.
- Mr. Heshmatpour owns an aggregate of 34.4% of the Company's fully diluted shares through AFH and affiliated entities.
- The Company entered into a new office lease for 1,427 sq ft in Calabasas, CA, starting April 14, 2025, with monthly rent starting at $6,778.25.
- Disclosure of significant debt conversions: A bridge loan from HCWG LLC (owned 31.25% by Mr. Heshmatpour) was converted to common stock in June 2024.
- The Company paid Mr. Heshmatpour $2,500,000 following its direct listing as part of an amended advisory agreement with AFH Holdings and Advisory, LLC.
NeOnc Technologies Holdings, Inc. entered into securities purchase agreements to issue common stock at $16.00 per share for approximately $1.6 million in gross proceeds. The funds are intended for working capital purposes.
🚩 Red Flags
- Small offering size ($1.6M) relative to typical micro-cap needs suggests potential liquidity constraints.
- Unregistered sale of equity securities (Rule 506(b)) can lead to future dilution and restricted liquidity for these shares.
📋 Key Facts
- Entered into securities purchase agreements on March 26, 2025.
- Offering price of $16.00 per share.
- Gross proceeds expected to be approximately $1.6 million.
- Shares are being issued under Section 4(a)(2) and Rule 506(b) exemptions (not registered).
- Proceeds are earmarked for working capital.
NeOnc Technologies Holdings, Inc. announced the resignation of Marcum LLP as its independent auditor and the appointment of CBIZ CPAs P.C., effective April 1, 2025. The filing notes that previous audits included an explanatory paragraph regarding the company's ability to continue as a going concern.
🚩 Red Flags
- Going concern language in previous audit reports (FY2023, FY2024).
- Multiple material weaknesses in internal controls identified by management.
- Specific weakness regarding 'lack of sufficient controls over related party transactions'.
- Auditor change occurring alongside existing going concern and control issues.
📋 Key Facts
- Marcum LLP resigned as the independent registered accounting firm on March 31, 2025.
- CBIZ CPAs P.C. was engaged as the new independent auditor effective April 1, 2025.
- Previous audit reports for FY2024 and FY2023 contained an explanatory paragraph regarding 'going concern' uncertainty.
- Management identified five material weaknesses in internal controls as of December 31, 2024: lack of segregation of duties, insufficient entity-level controls, insufficient controls over significant transaction classes, insufficient controls over related party transactions, and insufficient IT general controls.
NeOnc Technologies Holdings, Inc. has completed its direct listing on the Nasdaq Global Market under the ticker 'NTHI'. This filing details the adoption of amended and restated articles of incorporation and bylaws to facilitate this transition.
📋 Key Facts
- The company successfully executed a Direct Listing on the Nasdaq Global Market as of March 25, 2025.
- Ticker symbol is 'NTHI'.
- Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State on March 6, 2025.
- Amended and Restated Bylaws became effective on March 25, 2025, to comply with SEC universal proxy rules.